🇺🇸 FDA
Pipeline program

QT-019C

QH-HH-03

Phase 1 small_molecule active

Quick answer

QT-019C for Neuromyelitis Optica Spectrum Disorders is a Phase 1 program (small_molecule) at Tianjin Huanhu Hospital with 1 ClinicalTrials.gov record(s).

Program details

Company
Tianjin Huanhu Hospital
Indication
Neuromyelitis Optica Spectrum Disorders
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials